Primary Biliary Cirrhosis - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 125
Inquire Before Buying

Primary Biliary Cirrhosis - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H2 2018, provides an overview of the Primary Biliary Cirrhosis (Gastrointestinal) pipeline landscape.

Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 2, 12, 3, 1, 1 and 1 respectively.

Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Primary Biliary Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Primary Biliary Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Primary Biliary Cirrhosis - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Primary Biliary Cirrhosis - Overview
Primary Biliary Cirrhosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Primary Biliary Cirrhosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Primary Biliary Cirrhosis - Companies Involved in Therapeutics Development
Albireo Pharma Inc
Arena Pharmaceuticals Inc
Biocad
Cadila Healthcare Ltd
CymaBay Therapeutics Inc
Dr. Falk Pharma GmbH
Eisai Co Ltd
Enanta Pharmaceuticals Inc
Genfit SA
GenKyoTex SA
Gilead Sciences Inc
GlaxoSmithKline Plc
Intercept Pharmaceuticals Inc
Kowa Co Ltd
NGM Biopharmaceuticals Inc
Novartis AG
Tiziana Life Sciences Plc
Virobay Inc
Primary Biliary Cirrhosis - Drug Profiles
A-4250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCD-085 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-6011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDP-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elafibranor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etrasimod arginine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FFP-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
foralumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GKT-831 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-9674 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2330672 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
obeticholic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pemafibrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
saroglitazar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seladelpar lysine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tropifexor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ursodiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-825 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZG-5216 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Primary Biliary Cirrhosis - Dormant Projects
Primary Biliary Cirrhosis - Product Development Milestones
Featured News & Press Releases
Jun 05, 2018: Court Appoints Faruqi & Faruqi As Lead Counsel For Class Action Against Intercept Pharmaceuticals
May 07, 2018: Genkyotex Announces Positive Outcome from Independent SMB's First Pre-Planned Review of GKT831's Phase 2 Trial in Primary Biliary Cholangitis
Mar 28, 2018: Enanta Pharmaceuticals Announces Poster Presentations on EDP-305 at ICL 2018
Mar 23, 2018: Intercept Announces Multiple New Ocaliva (obeticholic acid) Data Presentations at the International Liver Congress 2018
Nov 01, 2017: Intercept Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
Jun 27, 2017: Genkyotex Initiates Patient Enrollment into Phase 2 Trial of GKT831 in Primary Biliary Cholangitis
May 02, 2017: Genkyotex Announces FDA Approval of IND for Phase 2 Trial of GKT831 in Patients with Primary Biliary Cholangitis
Apr 19, 2017: Intercept Announces New Ocaliva (obeticholic acid) and INT-767 Data to be Presented at EASL 2017
Apr 05, 2017: Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress 2017
Feb 23, 2017: Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis
Nov 04, 2016: GENFIT: FDA has officially cleared the IND to proceed with Phase II trial and evaluate elafibranor in PBC
Aug 17, 2016: New England Journal of Medicine Publishes Results of Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC
May 27, 2016: FDA Grants Accelerated Approval to Ocaliva (Obeticholic Acid) for the Treatment of Patients with PBC
May 18, 2016: Intercept Announces Ocaliva (Obeticholic Acid) Data in PBC to be Presented at DDW 2016
Apr 14, 2016: New Analyses of the Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC Presented at EASL
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Primary Biliary Cirrhosis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Primary Biliary Cirrhosis - Pipeline by Albireo Pharma Inc, H2 2018
Primary Biliary Cirrhosis - Pipeline by Arena Pharmaceuticals Inc, H2 2018
Primary Biliary Cirrhosis - Pipeline by Biocad, H2 2018
Primary Biliary Cirrhosis - Pipeline by Cadila Healthcare Ltd, H2 2018
Primary Biliary Cirrhosis - Pipeline by CymaBay Therapeutics Inc, H2 2018
Primary Biliary Cirrhosis - Pipeline by Dr. Falk Pharma GmbH, H2 2018
Primary Biliary Cirrhosis - Pipeline by Eisai Co Ltd, H2 2018
Primary Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals Inc, H2 2018
Primary Biliary Cirrhosis - Pipeline by Genfit SA, H2 2018
Primary Biliary Cirrhosis - Pipeline by GenKyoTex SA, H2 2018
Primary Biliary Cirrhosis - Pipeline by Gilead Sciences Inc, H2 2018
Primary Biliary Cirrhosis - Pipeline by GlaxoSmithKline Plc, H2 2018
Primary Biliary Cirrhosis - Pipeline by Intercept Pharmaceuticals Inc, H2 2018
Primary Biliary Cirrhosis - Pipeline by Kowa Co Ltd, H2 2018
Primary Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals Inc, H2 2018
Primary Biliary Cirrhosis - Pipeline by Novartis AG, H2 2018
Primary Biliary Cirrhosis - Pipeline by Tiziana Life Sciences Plc, H2 2018
Primary Biliary Cirrhosis - Pipeline by Virobay Inc, H2 2018
Primary Biliary Cirrhosis - Dormant Projects, H2 2018

List of Figures
Number of Products under Development for Primary Biliary Cirrhosis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • 2018-2023 Global Irritable Bowel Syndrome (IBS) Consumption Market Report
    Published: 20-Sep-2018        Price: US 4660 Onwards        Pages: 134
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Irritable Bowel Syndrome (IBS) market for 2018-2023. Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IB......
  • 2015-2023 World Drugs for Traveler's Diarrhea Market Research Report by Product Type, End-User / Application and Regions / Countries
    Published: 12-Sep-2018        Price: US 2800 Onwards        Pages: 97
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Market Segment as follows: By Region / Countries - North America (U.S., Canada, Mexico) - Europe (Germany, U.K., France, Italy, Russia, Spain etc) - South America (Brazil, Argentina etc)......
  • Gastric Ulcers - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 44
    Gastric Ulcers - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Ulcers - Pipeline Review, H2 2018, provides an overview of the Gastric Ulcers (Gastrointestinal) pipeline landscape. Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nausea or......
  • Celiac Disease - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 85
    Celiac Disease - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H2 2018, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape. Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk fa......
  • Pancreatitis - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 87
    Pancreatitis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatitis - Pipeline Review, H2 2018, provides an overview of the Pancreatitis (Gastrointestinal) pipeline landscape. Pancreatitis is an inflammation of pancreas. Symptoms include upper abdominal pain, nausea, vomiting, and tenderness when touching the abdomen, weight loss and upper abdominal pain. Predisposing factors inclu......
  • Alcoholic Hepatitis - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 76
    Alcoholic Hepatitis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcoholic Hepatitis - Pipeline Review, H2 2018, provides an overview of the Alcoholic Hepatitis (Gastrointestinal) pipeline landscape. Alcoholic hepatitis is an inflammation of the liver. It is typically caused by excessive alcohol consumption over a long period of time. Symptoms include changes in appetite, dry mouth, w......
  • Global Gastrointestinal OTC Drugs Market Insights, Forecast to 2025
    Published: 07-Sep-2018        Price: US 3900 Onwards        Pages: 124
    This report studies the global market size of Gastrointestinal OTC Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Gastrointestinal OTC Drugs in these regions. This research report categorizes the global Gastrointestinal OTC Drugs market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future tre......
  • Digital Landscape: Inflammatory Bowel Disease
    Published: 06-Sep-2018        Price: US 6000 Onwards        Pages: 159
    Digital Landscape: Inflammatory Bowel Disease Summary The Digital Landscape Inflammatory Bowel Disease report analyzes digital activities undertaken by pharma in support of disease-modifying therapies for mild-to-moderate, and moderate-to-severe Crohn's disease and ulcerative colitis (UC). Key Highlights - US Patients: AbbVie offers the strongest support for IBD patients in the US, particularly branded, unbranded and mobile app. Janssen......
  • Global Inflammatory Bowel Disease Partnering 2012 to 2018
    Published: 01-Sep-2018        Price: US 1995 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." The Global Inflammatory Bowel Disease Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs